Press Releases

November 30, 2021
Athenex to Host Key Opinion Leader Webinar on CAR-NKT Approach to Cancer
Presentations Will Include a Review of ANCHOR Study Data on KUR-502 from ASH Annual Meeting Webinar on Monday, December 13 th , at 9:00 a.m. ET BUFFALO, N.Y. , Nov. 30, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery,
Printer Friendly Version 
November 29, 2021
Athenex Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review
BUFFALO, N.Y. , Nov. 29, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its Marketing Authorization
Printer Friendly Version 
November 22, 2021
Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021
Analysis of safety data demonstrated that patients with elevated liver tests were at increased risk of neutropenia related toxicities Post hoc analysis of this subgroup of patients with hepatic impairment was conducted and showed a median survival rate of 18.9 months in patients treated with Oral
Printer Friendly Version 
November 18, 2021
Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference
BUFFALO, N.Y. , Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau , CEO and Board
Printer Friendly Version 
November 09, 2021
Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies
Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs to target solid tumors BUFFALO, N.Y. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel
Printer Friendly Version 
November 04, 2021
Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition
Results from five patients showed best responses of 2 partial responses (PR), 1 complete response with incomplete hematological recovery (CRi) and 1 complete response (CR). Updated data show continued favorable safety profile and encouraging anti-tumor activity in adult patients treated with low
Printer Friendly Version 
November 04, 2021
Athenex Provides Third Quarter 2021 Corporate and Financial Update
Held FDA Type A Meeting for oral paclitaxel in metastatic breast cancer Klisyri® launched in Europe ANCHOR Phase 1 interim results accepted for poster presentation at 2021 ASH 3Q product sales were $27.0M , up 9% year-over-year Company now expects full year product sales revenue in 2021 to decrease
Printer Friendly Version 
October 22, 2021
CORRECTION: Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021
BUFFALO, N.Y. , Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athenex   (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a
Printer Friendly Version 
October 21, 2021
Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 5, 2021
BUFFALO, N.Y. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athenex   (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a
Printer Friendly Version 
October 18, 2021
Athenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Cell Therapy
Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR) Patent protection helps validate the groundbreaking innovation of Dr.
Printer Friendly Version 
October 11, 2021
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer
BUFFALO, N.Y. , Oct. 11, 2021 (GLOBE NEWSWIRE) -- Athenex   (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it recently held a Type A meeting
Printer Friendly Version 
September 27, 2021
Athenex Announces Phased European Launch of Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis
Klisyri has been approved for the treatment of actinic keratosis by the UK Medicines and Healthcare products Regulatory Agency and will initially be available for prescription in the UK and Germany AK is one of the most common diagnoses made by dermatologists in Europe and Almirall plans to a
Printer Friendly Version 
September 16, 2021
Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021
Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging anti-tumor activity (4 PR out of 8 evaluable patients) in NSCLC patients who failed prior PD1/PDL1 therapies BUFFALO, N.Y. , Sept. 16, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc.
Printer Friendly Version 
September 15, 2021
Athenex to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & Med Tech Summit
BUFFALO, N.Y. , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau , CEO and
Printer Friendly Version 
August 05, 2021
Athenex Provides Second Quarter 2021 Corporate and Financial Update
Updated investors on FDA Type A Meeting for oral paclitaxel Klisyri ® approved by the European Commission in July 2021 KUR-501 GD2 CAR-NKT Phase 1 data in neuroblastoma presented at ASGCT 2021 Abstract for oral paclitaxel + pembrolizumab Phase 1 combination study accepted for ESMO Congress 2021
Printer Friendly Version 
July 26, 2021
Athenex Announces Additional Licensing Agreements for Tirbanibulin
Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada BUFFALO, N.Y. , July 26, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of
Printer Friendly Version 
July 22, 2021
Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021
BUFFALO, N.Y. , July 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a
Printer Friendly Version 
July 19, 2021
Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis
BUFFALO, N.Y. , July 19, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its partner, Almirall
Printer Friendly Version 
July 06, 2021
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer
BUFFALO, N.Y. , July 06, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company held a Type A
Printer Friendly Version 
June 04, 2021
Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program
Data from oral docetaxel phase I pharmacokinetic study shows oral administration can achieve exposure comparable to IV docetaxel Post-hoc subgroup efficacy analysis based on updated tumor subtypes in the oral paclitaxel phase III study demonstrated an improved response rate with oral paclitaxel
Printer Friendly Version 
May 21, 2021
Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp
European Commission Decision Anticipated by July 2021 BUFFALO, N.Y. , May 21, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related
Printer Friendly Version 
May 17, 2021
Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKT Cells in Neuroblastoma at ASGCT Annual Meeting
Data presented by investigators from the Texas Children’s Cancer Center One PR, one CR and four SDs out of 11 patients enrolled GD2 CAR NKT cells were well tolerated with no dose limiting toxicities CAR-NKT AUC normalized to disease burden (AUC/Curie score) was associated with response to therapy.
Printer Friendly Version 
May 06, 2021
Athenex Provides First Quarter 2021 Corporate and Financial Update
Plan to Request Type A Meeting with the FDA for Oral Paclitaxel by the End of May Klisyri® Launched in the U.S. in February 2021 Acquired Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform in May 2021 Management to Host Conference Call and Webcast at
Printer Friendly Version 
May 04, 2021
Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform
Transformative, leading allogeneic NKT cell platform technology expands Athenex’s cell therapy development capability Platform has broad applications based on transducing NKT cells with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to target hematological and solid cancers,
Printer Friendly Version 
April 27, 2021
Athenex to Provide Corporate and Financial Update for the First Quarter 2021 on May 6, 2021
BUFFALO, N.Y. , April 27, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a
Printer Friendly Version 
March 01, 2021
Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update
Receipt of Complete Response Letter from the FDA for Oral Paclitaxel Plus Encequidar Klisyri® (tirbanibulin) received FDA approval and launched commercially on February 18, 2021 The New England Journal of Medicine published Phase III trial data on the efficacy and safety of Klisyri® Product sales
Printer Friendly Version 
March 01, 2021
Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer
Conference call and webcast scheduled for today at 8:00 a.m. ET BUFFALO, N.Y. , March 01, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and
Printer Friendly Version 
February 22, 2021
Athenex to Provide a Corporate and Financial Update for the Fourth Quarter and Full Year 2020 on March 1, 2021
BUFFALO, N.Y. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a
Printer Friendly Version 
February 18, 2021
Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin
Athenex Announces Licensing of Additional Territories for the Development and Commercialization of Tirbanibulin in Japan and South Korea . PharmaEssentia Expands Tirbanibulin Partnership by Adding Japan and South Korea to Already Licensed Territories of Taiwan , Singapore , and Malaysia Athenex’s
Printer Friendly Version 
February 11, 2021
Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin)
The New England Journal of Medicine published the Phase III trial results on Klisyri®, an anti-proliferative agent that inhibits tubulin polymerization and Src kinase signaling, for the topical treatment of actinic keratosis (AK) of the face or scalp Klisyri®, developed by Athenex , received FDA
Printer Friendly Version 
January 25, 2021
CEO Dr. Johnson Lau Recuperating from COVID at Home
BUFFALO, N.Y. , Jan. 25, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its CEO and Board Chairman,
Printer Friendly Version 
January 08, 2021
CEO Dr. Johnson Lau Contracts COVID-19
BUFFALO, N.Y. , Jan. 08, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr.
Printer Friendly Version 
January 05, 2021
Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference
BUFFALO, N.Y. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it will participate in the 39 th
Printer Friendly Version